Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.

Journal: Cell

Published: 2020-08-05

DOI: 10.1016/j.cell.2020.08.002

Affiliations: 26

Authors: 45

Go to article
Institutions Share
Institute Gustave-Roussy (IGR), France 0.18
Tumour Immunology and Anti-Cancer Immunotherapy Unit, France 0.16
Cochin Hospital, France 0.16
Laboratory for Immunomonitoring in Oncology (LIO), France 0.10
Institut Cochin, France 0.10
Hôtel-Dieu de Paris, France 0.04
Sorbonne University, France 0.03
Weizmann Institute of Science (WIS), Israel 0.03
Singapore Immunology Network (SIgN), A*STAR, Singapore 0.03
Ecophysiologie et Génomique Fonctionnelle de la Vigne (EGFV), France 0.03
Molecular Predictors and New Targets in Oncology, France 0.03
Centre for Research in Epidemiology and Population Health (CESP), France 0.02
University of Paris-Saclay, France 0.02
Southern University of Science and Technology (SUSTech), China 0.01
Center of Bioinformatics, Biostatistics and Integrative Biology (C3BI), France 0.01
National Clinical Research Center for Infectious Diseases at Shenzhen Third People's Hospital, SUSTech, China 0.01
Center of Clinical Investigations in Biotherapies of Cancer (CICBT), France 0.01
Shanghai Jiao Tong University (SJTU), China 0.01
Duke-NUS Medical School, Singapore 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER